Sentences with phrase «applications for program approval»

In addition, the Commission reviews and processes CLE providers «applications for program approval.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Application for approval of this program has also been filed with the EMA.

Once the Permanent Phase application process opens in June 2018, health and wellness coach training and education programs may apply for ICHWC program approval.

A cost recovery plan offered Thursday to the Commission on Teacher Credentialing calls for universities and other teacher training institutions to pay $ 1,600 for an initial application approval and a similar amount for new program evaluation.

School districts shall submit an annual application for approval of those programs.

Parent Involvement in the School Program 2112.00 Parent Involvement Plan 2112.00 R1 Part - Time Classified Employees 6335.00 Part - Time Employees 6325.12 Payroll Deductions - Tax Sheltered Annuities 3921.00 Payroll Deductions - Tax Sheltered Annuities 3921.00 R1 Payroll Deductions - Tax Sheltered Annuities Approved Companies 3921.00 R3 Payroll Deductions - Tax Sheltered Annuity Deduction Agreement 3921.00 R1E1 Payroll Deductions - Tax Sheltered Annuity Requirements for all Vendors 3921.00 R2 Payroll Deductions - Tax Sheltered Life Insurance 3922.00 Performance Contract (Memorandum) 7116.30 E4 Performance Contract (Memorandum) 6222.10 E4 Performance Contract - $ 1,000 or less 7116.30 E2 Performance Contract - $ 1,000 or less 6222.10 E2 Performance Contract - over $ 1,000 not more than $ 5,000 6222.10 E3 Performance Contract - over $ 1,000, not more than $ 5,000 7116.30 E3 Performance Contract - Procedures 7116.30 R1 Performance Contract - Procedures 6222.10 R1 Performance Contract - Wage / Payment & Vendor / Contractor Determination 7116.30 E5 Performance Contract - Wage / Payment & Vendor / Contractor Determination 6222.10 E5 Performance Contracts 6222.10 Performance Contracts 7116.30 Personal Leave - All Employees 6225.00 R3 Personal Property Authorization 3934.00 E1 Personal Purchases by Employees 3872.00 Personnel Files 6410.00 Personnel Files 6410.00 R1 Petty Cash Purchase 3820.00 Physical Assaults and Threats 5610.00 Physical Examinations 6430.00 Physical Examinations 6430.00 R1 Positive Behavior Supports 8400.00 R1 Positive Behavior Supports and Interventions 8400.00 Post-Issuance Compliance for Tax Exempt and Tax Advantaged Obligations 3510.00 Post-Issuance Compliance for Tax Exempt and Tax Advantaged Obligations 3510.00 R1 Probationary Classified Employees 6343.00 Procedure for Workers» Compensation Insurance 6223.60 R1 Professional Staff Evaluation 6192.00 Program Evaluation 0540.00 R1 Program Evaluation 0540.00 Prohibition of Referral or Assistance Property Claim Form 3934.00 E2 Property Inventory 3220.00 Property Inventory 3220.00 R1 Proposed Guidelines for the Provision of Sex Education 7122.40 Public Complaints or Concerns 9600.00 Public Complaints or Concerns 9600.00 R1 Public Complaints or Concerns - Guidelines 9600.00 E1 Public Information Program 9120.00 Public Information Program 9120.00 R1 Public Records 8310.00 R1 Public Records 9110.00 Public Records 9110.00 R1 Public School Academies (Charter Schools) 2020.00 Public School Academies - Review and Approval of Application 2020.00 R1 Purchasing 3810.00 R1 Purchasing 3810.00 Purchasing - Department Responsibilities 3810.00 E1 Purchasing Cards 3810.00 R14

(c) The Secretary may terminate an experimental program for failing to meet the objectives established in the application or for noncompliance with State law or regulations not specifically waived in the Secretary's approval of the experimental program under subsection (a) upon 60 days notice.

With the approval of Prop. 51, $ 500 million is available for a new Charter School Facilities Program (CSFP) application filing round.

The program will help ease the transition for schools between application approval and the start - up phase; help ready schools for their first renewal process; help ease the anxiety some new charter school employees experience, even at established charter schools; as well as provide support for charter school authorizers and help them identify various high - quality authorizing best practices.

An interesting letter went out Tuesday from the U.S. Department of Education, asking interested colleges to submit applications for approval for federal financial aid for students in programs that take into account alternative measures — and not just credit hours — in awarding degrees.

(e) The board shall establish the information needed in an application for the approval of a charter school; provided that the application shall include, but not be limited to, a description of: (i) the mission, purpose, innovation and specialized focus of the proposed charter school; (ii) the innovative methods to be used in the charter school and how they differ from the district or districts from which the charter school is expected to enroll students; (iii) the organization of the school by ages of students or grades to be taught, an estimate of the total enrollment of the school and the district or districts from which the school will enroll students; (iv) the method for admission to the charter school; (v) the educational program, instructional methodology and services to be offered to students, including research on how the proposed program may improve the academic performance of the subgroups listed in the recruitment and retention plan; (vi) the school's capacity to address the particular needs of limited English - proficient students, if applicable, to learn English and learn content matter, including the employment of staff that meets the criteria established by the department; (vii) how the school shall involve parents as partners in the education of their children; (viii) the school governance and bylaws; (ix) a proposed arrangement or contract with an organization that shall manage or operate the school, including any proposed or agreed upon payments to such organization; (x) the financial plan for the operation of the school; (xi) the provision of school facilities and pupil transportation; (xii) the number and qualifications of teachers and administrators to be employed; (xiii) procedures for evaluation and professional development for teachers and administrators; (xiv) a statement of equal educational opportunity which shall state that charter schools shall be open to all students, on a space available basis, and shall not discriminate on the basis of race, color, national origin, creed, sex, gender identity, ethnicity, sexual orientation, mental or physical disability, age, ancestry, athletic performance, special need, proficiency in the English language or academic achievement; (xv) a student recruitment and retention plan, including deliberate, specific strategies the school will use to ensure the provision of equal educational opportunity as stated in clause (xiv) and to attract, enroll and retain a student population that, when compared to students in similar grades in schools from which the charter school is expected to enroll students, contains a comparable academic and demographic profile; and (xvi) plans for disseminating successes and innovations of the charter school to other non-charter public schools.

Applications must get Apple's approval before being allowed into the App Store at iTunes that serves as an exclusive shop for programs for iPhones, iPads, and iPod touch media players.

Conventional Loans Zero Down Home Loan Online Mortgage Loan 40 - Year Home Purchase Loans 40 - Year Home Mortgages Million Dollar Jumbo Home Loans Negative Amortization Home Loans Purchase Money Second Mortgage Payment Option ARM Mortgage Payment Option ARM Purchase Payment Option ARM 40 Year 80 - 20 Home Purchase 80 - 20 Mortgage Refinance 80 - 10 Purchase Mortgage FHA Home Mortgage VA Home Mortgage No Money Down Home Financing in Florida Atlanta Home Mortgage Rates Update Home Loan Programs Manufactured Home Loans Low Rate Home Mortgage Loans Manufactured Home Loan Financing Home Loans Foreclosed Homes Bank Owned Home Purchase Loans Short Sale Home Loans Down - Payment Assistance Home Purchase Loans New Home Loan Home Finance Purchase Loan Home Loan Interest Rates Home Loan Financing Cheap Home Loans Home Loans for Teachers Subprime Loans Home Financing with Bad Credit Mortgages for Bad Credit Mortgage Financing Mortgage Options Pre-Approved Mortgage Home Loan Application Home Loan Lenders Home Loan Approvals Will Rates Go Up On Rates for Home Purchase Loans?

Policies: This program has written policies This program works with purebred goldens This program does not require an application fee They adopt out of the service territory under special circumstances only: only special needs goldens are considered for out of area adoption Requires a dog be returned if the owner can not keep Takes ownership of a dog upon intake Requires a home visit before adoption approval Follows up with adopters after placement Dogs are observed and evaluated before adoption All dogs receive all vaccines (Rabies, DHLPP and any other regionally appropriate tests) before adoption All dogs have all tests (heartworm, fecal and other regionally appropriate tests) before adoption.

Upon receipt of the OCCI Site Application and proof of technician credentials (if preceptor is a veterinary technician) the file will be forwarded to the program director for preliminary approval.

Policies: This program has written policies This program works with purebred goldens This program does not require an application fee They adopt out of the service territory if applicant approved by other rescue and we have a dog compatible for them Requires a dog be returned if the owner can not keep Takes ownership of a dog upon intake Requires a home visit before adoption approval Follows up with adopters after placement Dogs are observed and evaluated before adoption All dogs receive all vaccines (Rabies, DHLPP and any other regionally appropriate tests) before adoption All dogs have all tests (heartworm, fecal and other regionally appropriate tests) before adoption.

Policy information: This program has written policies This program rescues Goldens and Golden mixes This program requires an application fee of $ 20 for home checks They do not adopt out of the service territory Requires a dog be returned if the owner can not keep it Takes ownership of a dog upon intake Requires a home visit before adoption approval Follows up with adopters after placement Dogs are observed and evaluated before adoption All dogs receive all vaccines (Rabies, DHLPP and any other regionally appropriate tests) before adoption All dogs have regionally appropriate tests before adoption.

For additional information on the Global Entry or TSA Pre ✓ ® programs, including information regarding the application and / or approval process and for a list of participating airlines and airports, as well as the full terms and conditions of the programs, please go to www.globalentry.gov for Global Entry and www.tsa.gov for TSA Pre ✓For additional information on the Global Entry or TSA Pre ✓ ® programs, including information regarding the application and / or approval process and for a list of participating airlines and airports, as well as the full terms and conditions of the programs, please go to www.globalentry.gov for Global Entry and www.tsa.gov for TSA Pre ✓for a list of participating airlines and airports, as well as the full terms and conditions of the programs, please go to www.globalentry.gov for Global Entry and www.tsa.gov for TSA Pre ✓for Global Entry and www.tsa.gov for TSA Pre ✓for TSA Pre ✓ ®.

The application for AMI approval shall be treated the same as an application for the approval of a driver education traditional course, and the AMI must deliver the school's approved curriculum as aligned with the Program of Organized Instruction for Driver Education and Traffic Safety.

Tags for this Online Resume: clinical, affairs, scientific, trials, innovative, management, summary, documents, submission, regulatory, 510 (k), ISE, ISS, PK / PD, communicating, monitoring, tactical, strategic, literature, direct, vision, Lead, Director, documentation, resources, execution, consensus, effectiveness, safety, CRA, IVD, medical, device, pharmaceutical, presentation, manuscript, abstract, poster, programs, leadership, career, development, appraisals, optimize, goals, objectives, internal, external, research, investigator, stakeholders, customers, prioritize, product, support, milestones, Microsoft, Word, Excel, statistics, data, analysis, Powerpoint, publication, growth, deliverables, diagnostic, prognostic, treatment, competitive, proven, ability, capable, assess, strategy, feasibility, methodology, design, develop, produce, recommend, recommendation, therapeutic, supervision, review, performance, appraisal, application, indication, company, collaborate, expert, justification, senior, executive, assessment, experienced, marketing, pre-market, pre-IDE, protocol, communication, utility, pharmacology, service, deliver, delivery, drug, metabolism, absorption, excretion, train, training, mentor, mentoring, CRO, reimbursement, XLSTAT, Prism, relationship, contract, consult, consultant, ownership, responsibility, authority, delegate, trends, direction, in - vitro, commercialize, commercialization, approval, clearance, patient, oncology, cancer, metabolic, cardiovascular, kidney, disease, health, outcomes, safe, effective, toxicity, novel, unique, unmet, need, advisors, advisory, committee, IRB, ethical, justified, supportive, care, associate

The Training Committee serves to identify and provide training opportunities for AFPM membership; promote training opportunities for APFM members; promote training provided by APFM members; and review applications for APFM approval of training programs.

For current Qualistar rated programs there will be a one for one cross walk over into Next Generation QRIS and accredited entities will have the option to apply for approval and will be included in Levels 3 and 4 based on their submitted applicatiFor current Qualistar rated programs there will be a one for one cross walk over into Next Generation QRIS and accredited entities will have the option to apply for approval and will be included in Levels 3 and 4 based on their submitted applicatifor one cross walk over into Next Generation QRIS and accredited entities will have the option to apply for approval and will be included in Levels 3 and 4 based on their submitted applicatifor approval and will be included in Levels 3 and 4 based on their submitted application.

REGISTRATION OPEN Presented by the Mediation Council of Illinois Friday May 4, 2018 8:30 - 4:30 Lewis University — Oak Brook Campus 7th Floor — Room 739AB 1111 W. 22nd Suite 700, Oak Brook, IL 60523 Lunch and Snacks Included This MCI program has applied to receive 6 continuing education credits for attorneys and application has been submitted to cosponsor Margaret S. Powers and Associates, and is pending approval for all Licensed Mental Health Providers.